Stock Events

Soligenix 

$4.77
47
+$0+0% Today

Statistics

Day High
4.77
Day Low
4.77
52W High
5.6
52W Low
0.42
Volume
186
Avg. Volume
8,171
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

10MayConfirmed
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.3
-0.89
-0.47
-0.06
Expected EPS
-0.2
Actual EPS
-0.18

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0A6I.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap14.79B
Incyte Corporation operates in the same biopharmaceutical sector focusing on innovative therapies, directly competing in areas of immunology and oncology similar to Soligenix's pipeline.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops and markets drugs in areas overlapping with Soligenix's focus, including treatments for infectious diseases, potentially competing in the development of treatments for conditions like COVID-19.
AMGEN
AMGN
Mkt Cap177.72B
Amgen Inc. competes in the biotech space, focusing on innovative human therapeutics. Their work in immune-oncology and inflammatory diseases competes with Soligenix's research and product development.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biopharmaceuticals, directly competing with Soligenix in the development of treatments for rare diseases and conditions requiring novel therapeutic approaches.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.85B
Vertex Pharmaceuticals Incorporated operates in the biotechnology industry, focusing on creating new possibilities in medicine. Their work on cystic fibrosis and other serious diseases competes with Soligenix's efforts in rare diseases.
Biogen
BIIB
Mkt Cap32.96B
Biogen Inc. focuses on neurology, autoimmune and rare diseases, areas that overlap with Soligenix's therapeutic development, making them a competitor in the biopharmaceutical market.
Novo Nordisk
NVO
Mkt Cap445.94B
Novo Nordisk A/S is a global healthcare company with a strong focus on diabetes care and other serious chronic conditions, potentially competing with Soligenix in the broader healthcare market.
Pfizer
PFE
Mkt Cap169.83B
Pfizer Inc. is a global biopharmaceutical company with a wide range of products in various therapeutic areas, including those that compete with Soligenix's focus areas.
Merck &
MRK
Mkt Cap318.55B
Merck & Co., Inc. operates globally in pharmaceuticals, offering products that directly compete with Soligenix's in areas like oncology and infectious diseases.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson is a broad healthcare company that, through its pharmaceutical division, competes with Soligenix in developing treatments for a wide range of diseases, including areas of focus for Soligenix.

About

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Show more...
CEO
Dr. Christopher J. Schaber Ph.D.
Employees
13
Country
United States
ISIN
US8342236044
WKN
000A2AS7Q

Listings